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ABSTRACT
Hepatocellular carcinoma (HCC) is characterized by the accumulation of unfolded 
proteins in the endoplasmic reticulum (ER), which activates the unfolded protein 
response (UPR). However, the role of ER stress in tumor initiation and progression is 
controversial. To determine the impact of ER stress, we applied tauroursodeoxycholic 
acid (TUDCA), a bile acid with chaperone properties. The effects of TUDCA were 
assessed using a diethylnitrosamine-induced mouse HCC model in preventive 
and therapeutic settings. Cell metabolic activity, proliferation and invasion were 
investigated in vitro. Tumor progression was assessed in the HepG2 xenograft model.
Administration of TUDCA in the preventive setting reduced carcinogen-induced 
elevation of alanine and aspartate aminotransferase levels, apoptosis of hepatocytes 
and tumor burden. TUDCA also reduced eukaryotic initiation factor 2α (eIf2α) 
phosphorylation, C/EBP homologous protein expression and caspase-12 processing. 
Thus, TUDCA suppresses carcinogen-induced pro-apoptotic UPR. TUDCA alleviated 
hepatic inflammation by increasing NF-κB inhibitor IκBα. Furthermore, TUDCA altered 
the invasive phenotype and enhanced metabolic activity but not proliferation in HCC 
cells. TUDCA administration after tumor development did not alter orthotopic tumor 
or xenograft growth. Taken together, TUDCA attenuates hepatocarcinogenesis by 
suppressing carcinogen-induced ER stress-mediated cell death and inflammation 
without stimulating tumor progression. Therefore, this chemical chaperone could 
represent a novel chemopreventive agent.
INTRODUCTION
Hepatocellular carcinoma (HCC) ranks as the second 
leading cause of cancer-related mortality worldwide and is 
frequently associated with liver cirrhosis [1, 2]. Resection 
and transplantation are the only potentially curative 
treatments available following detection of a small HCC 
[1]. For the majority of patients with locally advanced 
disease, however, the multi-kinase inhibitor sorafenib 
and transarterial embolization are the only approved 
treatments. Unfortunately, both of these treatments provide 
a limited survival benefit [1]. Given that risk factors for 
HCC, such as liver cirrhosis, are fairly well established, 
chemopreventive strategies may help combat the disease. 
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Ideally, these drugs should be safe for long-term use in the 
at-risk population. However, no chemopreventive drugs are 
currently available for HCC [3].
Tauroursodeoxycholic acid (TUDCA) is a hydrophilic 
bile acid that is produced endogenously in humans at very 
low levels [4]. TUDCA is synthesized in the conjugation 
pathway of ursodeoxycholic acid, which is effectively used 
for treating cholestatic liver diseases, including primary 
biliary cirrhosis, without major adverse reactions [4]. 
These hydrophilic bile acids act as bile secretagogues and 
immunomodulators that can prevent apoptosis induced by 
several agents, such as hydrophobic bile acids, alcohol, 
transforming growth factor β1, and Fas ligand, in hepatic 
and non-hepatic cells [5, 6]. In addition, TUDCA protects 
rat livers during long-term ethanol feeding [7] and human 
livers from ischemia-reperfusion injury during harvesting 
and cold storage [8]. The mechanisms involved in the 
antiapoptotic properties of TUDCA include targeting 
mitochondrial function and integrity and interactions with 
the nuclear factor kappa-B (NFκB) signaling pathways [9].
The endoplasmic reticulum (ER) is an important 
organelle required for cell survival and is highly sensitive 
to homeostatic alterations. Disruption of ER homeostasis 
leads to the accumulation of unfolded proteins, which 
disturb ER function and result in a state known as ER 
stress [10]. In resting cells, all ER stress receptors are 
maintained in an inactive state through association with 
the ER chaperone glucose-regulated protein, 78 kDa 
(Grp78). Upon ER stress, Grp78 dissociates and triggers 
the unfolded protein response (UPR), which orchestrates 
cellular adaptation to stress by inducing transcriptional 
programs and by repressing global translation by 
eukaryotic initiation factor 2α (eIf2α) phosphorylation 
[11]. However, if the stress is too severe, UPR signaling 
switches from a pro-survival to a pro-apoptotic state, 
leading to increased pro-apoptotic transcription factor 
C/EBP homologous protein (Chop) expression and the 
cleavage of procaspase-12 to its active caspase-12 form 
[11]. Interestingly, the UPR is activated in several liver 
diseases, including fatty liver disease, viral hepatitis, 
alcohol-induced liver injury and HCC [12, 13].
Importantly, TUDCA has been shown to act as a 
chemical chaperone that decreases UPR signaling and 
protects hepatocytes against cytotoxicity caused by the ER 
stress inducer thapsigargin [14, 15]. TUDCA has also been 
shown to abolish ER stress-induced caspase-12 processing 
and to subsequently inhibit effector caspases-3/7 activation 
and apoptosis [15].
Recent studies have demonstrated that hepatocyte 
apoptosis is a pathogenic event in several liver diseases 
[13, 16]. Chronically increased hepatocyte apoptosis 
in genetic mouse models is carcinogenic and leads to 
compensatory liver regeneration, oxidative stress and DNA 
hypermethylation [16, 17]. In this study, we investigated the 
preventive and therapeutic potential of TUDCA in HCC. 
Our data demonstrate that TUDCA reduces carcinogen-
induced liver dysfunction and HCC incidence, likely 
through the prevention of ER stress-induced apoptosis 
and inflammation. Importantly, once HCC nodules are 
established, TUDCA does not modulate tumor growth.
RESULTS
Preventive administration of TUDCA reduces 
HCC burden in an orthotopic mouse model
The ER stress-inducing hepatocarcinogen diethy-
lnitrosamine (DEN) promotes multifocal HCC after 25 
weeks of administration [18, 19]. To explore the effects of 
TUDCA on hepatocarcinogenesis, we supplemented the 
animals with low or high dose TUDCA in their drinking 
water. Administration of DEN resulted in reduced body 
weights and 25% increased mortality (p < 0.001; Table 1) 
compared to saline administration. TUDCA treatment did 
Table 1: Mouse body weight (g) (mean ± SD)
Group Average body weight 25 weeks (g) Average body weight 30 weeks (g) Survival (%)
Preventive study
Saline 31.22 ± 1.39 100
DEN + control 26.75 ± 1.96*** 75
DEN + low dose TUDCA 27.39 ± 1.45# 83
DEN + high dose TUDCA 24.64 ± 2.17# 67
Therapeutic study
DEN ⇒ control 25.96 ± 3.65 22.92 ± 3.19 67
DEN ⇒ low dose TUDCA 23.86 ± 2.70 22.13 ± 2.57¥ 75
DEN ⇒ high dose TUDCA 24.53 ± 2.13 23.43 ± 2.61¥ 67
***p < 0.001: 25 weeks DEN vs. saline.
#not significant compared to DEN + control.
¥not significant compared to DEN ⇒ control.
DEN, diethylnitrosamine.
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not affect the weight loss or mortality of DEN-treated 
mice, and no clinical signs of toxicity were observed in 
any of the TUDCA-treated groups.
DEN-treated mice that received low- or high-
dose TUDCA developed fewer nodules per liver (all 
sizes: 18.9 ± 5.3 after vehicle versus 11.5 ± 3.9 after 
low-dose TUDCA [p < 0.01] and 12.3 ± 4.1 after high-
dose TUDCA [p < 0.05]). HCC burden, quantified 
by the loss of reticulin staining, was reduced in DEN-
treated mice following the co-administration of low- or 
high-dose TUDCA (p < 0.01; Figure 1A–1C). Choline 
positron emission tomography, which visualizes cellular 
membrane biosynthesis, demonstrated that administration 
of low-dose TUDCA in DEN-treated mice resulted in 
fewer hepatic loci with high mean standardized uptake 
values compared with animals receiving vehicle alone 
(p < 0.05; Figure 1D–1E). Repeated DEN administration 
induces HCC in a background of liver fibrosis [18]. 
However, no difference in grade of fibrosis, as determined 
by Sirius Red staining, was found between TUDCA- and 
vehicle-treated livers (data not shown).
DEN administration increased the levels of serum 
ALT and AST compared to saline administration (p < 
0.001; Figure 2A). Importantly, serum ALT and AST levels 
were reduced in DEN-treated mice receiving TUDCA-
supplemented drinking water compared to those receiving 
regular drinking water (p < 0.05; Figure 2A). This suggests 
that both low- and high-dose TUDCA protect the liver 
from DEN-induced hepatotoxicity. Collectively, these data 
indicate that TUDCA decreases the susceptibility of mice to 
DEN-induced hepatocarcinogenesis in a preventive setting.
TUDCA attenuates UPR-induced apoptosis in 
DEN-treated mice
Repeated DEN administration results in significant 
apoptosis and ER stress in hepatocytes [18, 19]. We 
measured the activity of effector caspase-3/7 ex vivo and, as 
expected, observed increased levels in DEN-treated mouse 
livers (p < 0.001, Figure 2B). Interestingly, the hepatic 
caspase-3/7 activity was lower in DEN/TUDCA-treated 
mice compared to DEN/vehicle-treated mice (Figure 2B). 
In agreement with these data, TUNEL immunofluorescence 
demonstrated a significant reduction of TUNEL-positive 
hepatocytes following TUDCA supplementation (p < 
0.05, Figure 2C–2D), thus confirming reduced hepatocyte 
apoptosis upon DEN challenge.
Grp78 and Chop expression and eIf2α phosphory-
lation were increased in the mice treated with DEN, 
reflecting robust UPR activation (Figure 3A–3B). As a 
positive control, tunicamycin, a nucleoside antibiotic that 
inhibits protein glycosylation and thereby elicits acute 
ER stress [11], was administered to naive mice. These 
control mice showed significantly increased expression of 
Grp78 and Chop and eIf2α phosphorylation (Figure 3B). 
Administration of TUDCA during the 25 weeks of 
carcinogen exposure consistently reduced the expression 
of Grp78 and Chop and inhibited eIf2α phosphorylation, 
thereby possibly restoring global translation (Figure 3A–3B). 
Caspase-12, the central player in ER stress-induced apoptosis 
[11], was markedly activated by both tunicamycin and 
DEN administration, whereas TUDCA reduced the DEN-
induced cleavage of procaspase-12 (p < 0.05; Figure 3C). 
Overall, these data strongly suggest that TUDCA decreases 
carcinogen-induced ER stress and thereby attenuates caspase-
12-mediated hepatocyte apoptosis.
TUDCA increases cellular metabolic activity 
independent of ER stress
To further explore the effect of TUDCA on cell 
viability and proliferation, HepG2, BWTG3 and Hepa1-6 
cells were incubated with a dilution series of TUDCA. 
As shown by lactate dehydrogenase (LDH) activity in 
the cell supernatant, TUDCA at 0.1–1 mM did not induce 
cytotoxicity in HepG2 cells (Supplementary Figure 
S1A). At 10 mM, however, TUDCA increased the LDH 
activity (p < 0.001). Next, we examined the effect of 
TUDCA on the MTT metabolic activity of cells under 
basal conditions. The reduction of tetrazolium salts such 
as MTT depends on both cellular metabolic activity 
and proliferation rate. Intriguingly, 0.1–1 mM TUDCA 
increased the MTT metabolic activity of HepG2 cells in 
a dose-dependent manner to supranormal levels of up 
to 150% (p < 0.001; Figure 3D). Incorporation of the 
thymidine analogue bromodeoxyuridine (BrdU) into the 
DNA of HepG2 cells under basal conditions showed that 
TUDCA modestly decreased the cell proliferation rate at 
1 mM (p < 0.05, Supplementary Figure S1B). Furthermore, 
we directly counted HepG2 cells after 48 h of incubation 
with 0.1–1 mM TUDCA and found no difference in cell 
number compared to controls (data not shown). The MTT 
metabolic activity and BrdU incorporation experiments 
were repeated in BWTG3 and Hepa1-6 cells with similar 
results (Supplementary Figure S1C–S1F). These data 
suggest that, under basal conditions, TUDCA dose-
dependently enhances cellular metabolic activity without 
increasing the absolute number of cells.
Next, we examined whether TUDCA would have the 
same effects in the presence of ER stress [11]. Tunicamycin 
(0.5 μg/ml) did not alter MTT metabolic activity or LDH 
release in HepG2 cells, suggesting no inherent cytotoxicity 
at the concentration used (Figure 3D and Supplementary 
Figure S1A, respectively). However, tunicamycin did impair 
BrdU incorporation (p < 0.01; Supplementary Figure S1B), 
confirming the well-known ER stress-mediated induction of 
cell cycle arrest [11]. Finally, TUDCA was able to enhance 
cellular metabolic activity even in the presence of acute ER 
stress (Figure 3D and Supplementary Figure S1C–S1D); 
however, this had no effect on the antiproliferative effect of 
ER stress (Supplementary Figure S1B and Supplementary 
Figure S1E–S1F).
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Figure 1: TUDCA prevents the development of HCC during carcinogen exposure. A. Representative images of livers treated 
for 25 weeks with the indicated treatments. B. Quantitative analysis of the tumor burdenas assessed by C. Reticulin staining. Scale bar: 100 
μm. D. 18F-Choline positron emission tomography was performed to visualize cell membrane synthesis after the indicated treatments (blue: 
low, red: high activity). E. Quantification of 18F-Choline positron emission tomography. Standardized uptake values of the mouse livers are 
presented as the mean ± SD. One-way ANOVA was applied for statistical analysis. *p < 0.05, **p < 0.01.
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Figure 2: TUDCA reduces DEN-induced apoptosis of hepatocytes. A. Liver damage was assessed by measuring ALT and AST 
levels in the serum of mice after the indicated treatments. B. Caspase-3/7 activity ex vivo (n = 8). C. TUNEL immunofluorescence and  
D. quantification of the TUNEL-positive index.*p < 0.05, **p < 0.01, ***p < 0.001.
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TUDCA does not reduce oxidative stress-induced 
cell death or DEN-induced oxidative stress
TUDCA has been shown to exert cytoprotective 
effects in different models by reducing oxidative stress 
[20], and ER stress is closely connected to the oxidative 
stress response [10]. Thus, we evaluated the effect of 
TUDCA on the cytotoxicity of H2O2-induced oxidative 
stress in HepG2 cells. Cell viability declined following the 
addition of 1–5 mM of H2O2 in a dose-dependent manner 
(Supplementary Figure S2A). In contrast to the established 
antioxidant properties of N-acetylcysteine, co-incubation 
with 0.1 or 1 mM TUDCA did not protect HepG2 cells 
against H2O2-induced cell death (p < 0.01; Supplementary 
Figure S2A).
In the orthotopic HCC model, TUDCA supplemen-
tation did not alter the expression levels of DEN-induced 
antioxidant response genes such as glutathione-S-
transferase A1 (Gsta1), glutathione-S-transferase A2 
(Gsta2), nuclear factor erythroid-derived 2 like 2 (Nfe2l2) 
and glutamate-cysteine ligase (Gclc; Supplementary 
Figure S2B). Malondialdehyde (MDA) is a toxic 
product of reactions between reactive oxygen species 
(ROS) and polyunsaturated lipids that is commonly 
Figure 3: Effect of TUDCA on the hepatic UPR pattern in the DEN-induced mouse model of HCC. A. Real-time PCR 
analysis of the UPR targets Grp78 and Chop. B. Expression of Grp78, eIf2α, phospho-eIf2α, Chop, procaspase-12 and cleaved caspase-12 was 
detected using Western blotting. Results are representative of 2 independent experiments. C. Cleaved caspase-12/procaspase-12 ratio obtained 
using densitometric analysis of the Western blot shown in B. D. Effect of TUDCA treatment on the MTT metabolic activity of HepG2 cells 
(treated with tunicamycin (Tunica) or not). *p < 0.05, **p < 0.01, ***p < 0.001. Results are representative of 3 independent experiments.
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used as a biomarker to quantify oxidative stress. DEN 
administration resulted in substantial accumulation of 
MDA protein adducts (p < 0.001), and this was found to 
be unaltered by TUDCA supplementation (Supplementary 
Figure S2C). Thus, the chemopreventive action of TUDCA 
seems to be independent of oxidative stress.
TUDCA does not affect DEN-induced 
autophagic flux
ER stress is able to induce autophagy [21], which 
has been shown to protect against hepatocarcinogenesis 
[22]. We therefore tested whether TUDCA modulates 
autophagy in vivo (Supplementary Figure S3). DEN-
treated liver tissue exhibited enhanced expression of 
Beclin-1 and increased conversion of LC3B-I to LC3B-II, 
indicating the activation of autophagic signals. The cellular 
content of p62, a receptor and substrate of selective 
autophagy, is a critical indicator of autophagic flux 
[23]. Immunoblotting for p62 showed that DEN slightly 
decreased the hepatic p62 content (Supplementary Figure 
S3A). TUDCA administration did not alter the stably 
elevated LC3 conversion and reduced p62 content. Thus, 
TUDCA was unable to alter the enhanced autophagic flux.
TUDCA attenuates DEN-induced hepatic 
inflammation
Human HCC usually develops in the background 
of chronic hepatic inflammation [1]. Repeated DEN-
induced murine tumors share similar pathogenesis [18], 
where pro-inflammatory cytokines, such as interleukin-6 
(IL-6) and tumor necrosis factor-α (Tnf-α), promote 
tumor development [24]. Indeed, accumulating evidence 
suggests extensive cross-talk between the UPR and 
the inflammatory response [25]. Chop-deficient livers 
have been shown to exhibit reduced inflammation and 
hepatocarcinogenesis [26]. Because TUDCA abolished 
the DEN-induced Chop expression in our study, we 
hypothesized that TUDCA might alter DEN-induced 
hepatic inflammation. Immunohistochemical staining 
demonstrated robust accumulation of F4/80+ macrophages 
in the livers of animals treated with DEN for 25 weeks 
(Figure 4A–4B). However, TUDCA significantly decreased 
the number of liver-infiltrating macrophages (p < 0.05). 
Using multiplex microbead immunoassays, we observed 
that hepatic expression of inflammatory cytokines, 
including interleukin-1 beta (IL-1β), IL-6, keratinocyte-
derived chemokine (KC), monocyte chemoattractant 
protein-1 (Mcp-1), and Tnf-α, was augmented following 
DEN administration. Importantly, IL-6 (p < 0.05), KC (p < 
0.05) and Tnf-α (p < 0.01) levels were reduced following 
TUDCA supplementation (Figure 4C).
Elevated eIf2α phosphorylation leads to 
translational repression of the NF-κB inhibitor IκBα 
and thereby promotes NF-κB signaling [27], which 
exerts a pro-carcinogenic role in inflammation-related 
hepatocarcinogenesis [28]. Using salubrinal, which inhibits 
eIf2α de-phosphorylation, we confirmed that sustained eIf2α 
phosphorylation leads to translational repression of IκBα in 
HepG2 cells (data not shown). Because DEN-induced eIf2α 
phosphorylation was abolished by TUDCA supplementation 
(Figure 3B), we assessed the effect of TUDCA on hepatic 
IκBα expression and NF-κB activation to investigate this 
potential mechanism of action. Interestingly, TUDCA 
supplementation restored IκBα expression and slightly 
decreased phospho-NFκB p65 levels, the active form of 
NF-κB, in the DEN-treated livers (Figure 4D–4E). These 
data indicate that TUDCA suppresses the immune response 
to DEN-induced liver injury by reducing phospho-eIf2α-
mediated repression of IκBα translation.
TUDCA alters invasiveness in vitro
Because ER stress was previously linked to cell 
invasion [29, 30], we questioned whether TUDCA could 
modify HCC cell invasion in vitro. Therefore, we examined 
the effect of TUDCA in a hepatocyte growth factor-induced 
invasion assay in which spheroids of the Hepa1-6 HCC 
cell line embedded in collagen matrix were observed over 
time (Figure 5A–5C). TUDCA decreased the sphere area 
after 60 h of incubation (p < 0.05; Figure 5A), whereas 
the perimeter of the TUDCA-treated spheres increased 
compared with controls after 24 (p < 0.001) and 48 h 
(p < 0.05) of incubation (Figure 5B). Although TUDCA may 
have decreased sphere area by affecting cell proliferation in 
this context (e.g., as observed for HepG2 in Figure 3B), the 
larger perimeter combined with a smaller area suggests an 
altered invasive phenotype. This result was also supported 
by the more irregular sphere shape observed upon invasion 
in the presence of TUDCA (Figure 5C). However, in a 
Boyden chamber assay, addition of 1–2 mM of TUDCA 
induced no significant alterations in the hepatocyte growth 
factor-stimulated invasion of the HCC cells over a 48-hour 
period (Figure 5D).
Degradation of the extracellular matrix is one 
pivotal step and occurs due to the actions of matrix 
metalloproteinases (MMP). MMP-2, MMP-9 and MMP-
14 enzymes play important roles in the degradation of the 
extracellular matrix and exist extensively in HCC tissues. 
MMP profiling showed that addition of TUDCA did not 
alter the protein levels of MMP-2, -9 and -14 (Figure 5E). 
Accordingly, we observed no changes in the extracellular 
MMP-2 and -9 activity in the concentrated conditioned 
medium (Figure 5F). In conclusion, although TUDCA 
alters the invasive phenotype, TUDCA does not induce 
increased HCC cell invasion.
TUDCA did not affect tumor progression
Given our findings that TUDCA attenuated UPR-
induced apoptosis and increased cellular metabolic 
activity, we evaluated whether TUDCA could stimulate 
tumor progression via its cytoprotective effect. To 
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Figure 4: Effect of TUDCA on DEN-induced hepatic inflammation. A. Immunostaining for F4/80 and B. quantification of 
F4/80-positive macrophages in the liver after the indicated treatments (n = 5). C. Determination of the indicated hepatic cytokine levels 
by multiplex microbead immunoassay (n = 8). Values represent the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001. D. Expression of 
IκBα, phospho-NFκB p65 and NFκB p65 was detected using Western blotting. Results are representative of 2 independent experiments. E. 
Phospho-NFκB p65/ NFκB p65 ratio obtained using densitometric analysis of the Western blot shown in D.
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Figure 5: Effects of TUDCA on HCC cell invasion. A. The area and B. length of the outside boundary (perimeter) of collagen-
embedded Hepa1-6 spheroids (n = 9) was measuredat 0, 24, 48 and 60 h of incubation with 2 mM TUDCA or control medium. Results 
are representative of 2 independent experiments. C. Representative images of invasive capacity of cells present in a collagen-embedded 
multicellular spheroid are shown at different time points. The multicellular spheroids are approx. 150 μm in diameter at start. At 60 h, the 
spheroid perimeter is marked. Scale bar is 50 μm. D. Boyden chamber invasion assay with Hepa1-6 cells following 48 h of incubation with 
control medium, control medium with chemoattractant hepatocyte growth factor (HGF) without or with 1–2 mM TUDCA. Samples were 
run in quadruplicate. E. Western blot analysis of MMP-2, -9 and -14 levels in Hepa1-6 cell lysates of control cells and cells treated with 
1 or 2 mM TUDCA (48 h), in the presence or absence of 50 ng/ml HGF stimulation. Arrows indicate MMP-2 (72 and 63–66 kDa), MMP-
9 (78–82 kDa) and MMP-14 (66–57 kDa). The β-actin signal is used as loading control. F. Gelatin zymography of concentrated culture 
medium of Hepa1-6 control cells or cells treated with 1 or 2 mM TUDCA (48 h), in the presence or absence of 50 ng/ml HGF stimulation. 
The white bands indicate MMP-activity; arrowheads: signal for MMP-9 (glycosylated, 92 kDa) and MMP-2 (58/62 kDa, active). Values 
represent the mean ± SD. *p < 0.05, ***p < 0.001.
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assess the effect of TUDCA on established tumors, 
we used orthotopic and xenograft mouse models of 
HCC. Following orthotopic HCC induction with 25 
weeks of DEN, 5 weeks of low- or high-dose TUDCA 
supplementation had no significant effect on mortality 
(Table 1) or tumor number (all sizes: 17.4 ± 4.9 after 
vehicle versus 19.7 ± 4.5 after low-dose TUDCA and 18.8 
± 5.3 after high-dose TUDCA). Accordingly, microscopic 
quantification confirmed that TUDCA produced no 
significant effects on HCC burden (Figure 6A–6C). 
Next, we investigated the effects of 5 weeks of TUDCA 
supplementation following 25 weeks of DEN-induced 
tumor development on the UPR (Figure 6D–6E). TUDCA 
did not alter the protein levels of Chop or phospho-eIf2α in 
HCC-bearing livers (Figure 6E). Moreover, no difference 
in the apoptosis rate was observed (data not shown). These 
results suggest that TUDCA was unable to restore ER 
function after prolonged hepatocarcinogen exposure.
In the HepG2 xenograft model, TUDCA 
supplementation for 5 weeks did not significantly modify 
tumor growth compared to control treatment (Figure 6F–
6G), and no mortality occurred in any of these groups. 
Finally, no metastases were detected in any group of the 
preventive or therapeutic settings of the orthotopic or of 
the HepG2 xenograft model.
DISCUSSION
There is an urgent need for innovative preventive 
and therapeutic options for HCC [3]. Previous studies 
have demonstrated that the chemical chaperone TUDCA 
serves as a cytoprotective agent by reducing ER stress 
and apoptosis [5, 7, 8, 14]. In this study, we evaluated 
the preventive and therapeutic potential of TUDCA 
and its effect on carcinogen-induced ER stress in HCC. 
Our results reveal that TUDCA supplementation during 
carcinogen exposure reduces the carcinogen-induced 
apoptosis of hepatocytes and HCC incidence (Figure 7). 
Furthermore, it does not stimulate the progression and 
invasion of established tumors
A recent double-blind randomized trial demonstrated 
that daily TUDCA therapy (750 mg) for 6 months is safe 
and appears to be an effective liver cirrhosis treatment; 
in particular, it improved several biochemical parameters 
[31]. In addition, TUDCA therapy in cirrhotic patients 
awaiting liver transplantation supported their functional 
stability during the wait time [32]. Our results suggest that 
TUDCA therapy in patients with a high HCC risk, such as 
cirrhotic patients with continuous exposure to carcinogens, 
not only improved liver function but could also prevent 
HCC incidence.
We selected a low dosage (60 mg/kg/day), which 
corresponds to dosages administrable and tolerable for 
humans, and a high dosage (300 mg/kg/day) to assess 
dose-dependent effects and potential side effects. Both 
low- and high-dose TUDCA administration decreased 
tumor burden in our mouse models. However, the trend 
of reduced weight and survival was only observed in 
the high-dose TUDCA group. This reduction in body 
weight was also observed in a mouse model of retinitis 
pigmentosa, where animals were treated with high-dose 
TUDCA (500 mg/kg/day) [33]. Additionally, TUDCA has 
been shown to increase energy expenditure by promoting 
intracellular thyroid hormone activation [34]. Therefore, 
a low dose of TUDCA is advisable for chemoprevention.
Chemically improving the ER folding capacity by 
TUDCA administration was previously shown to protect 
from UPR signaling and ER stress-induced apoptosis, 
which are primarily regulated by the phospho-eIf2α\
Chop cascade [10, 15]. Although Chop plays critical 
pro-apoptotic roles, it was recently shown to promote 
carcinogenesis in a DEN-induced model of HCC [26]. 
Accordingly, TUDCA efficiently diminished Chop 
expression and tumorigenesis during carcinogen exposure 
in our study.
In hepatocytes, DEN is metabolized by cytochrome 
P450 2E1 through a ROS-generating reaction that induces 
liver injury and DNA damage [35, 36]. Subsequently, 
danger signals released from injured hepatocytes induce 
liver inflammation. Accordingly, certain antioxidants, 
such as N-acetylcysteine [35] or lycopene [37], have been 
shown to attenuate DEN-induced hepatocarcinogenesis. 
Of note, N-acetylcysteine was recently shown to accelerate 
lung cancer progression in mice [38]. Because TUDCA 
did not affect oxidative stress-induced cytotoxicity in 
vitro or hepatic oxidative stress in vivo, we presume that 
the chemopreventive effect of TUDCA was not mediated 
by directly antagonizing oxidative stress but rather by 
modulating ER stress-induced apoptosis. Therefore, the 
combination of TUDCA with antioxidants could represent 
a dual-targeting chemopreventive strategy for HCC.
HCC has been characterized as a chronic 
inflammation-driven cancer, and chemically induced 
models have revealed the crucial roles of inflammatory 
signaling in disease onset and severity [35]. Therefore, we 
assessed whether TUDCA affected tumor-immune system 
crosstalk. TUDCA administration resulted in a decrease in 
hepatic macrophage infiltration and IL-6, KC and Tnf-α 
levels. These results suggest that TUDCA attenuates 
inflammation in response to DEN-induced liver injury 
and thus interrupts positive feedback from inflammation-
induced ER stress and UPR-induced inflammation [13]. 
Interestingly, a similar effect of TUDCA on macrophage 
infiltration and Tnf-α expression was also recently 
observed in a model of ER stress-mediated steatohepatitis-
induced HCC [39]. However, additional studies are needed 
to uncover the precise mechanism of the interaction 
between ER stress and inflammation and the effects of 
TUDCA on these signaling pathways.
Uncontrolled regeneration of hepatocytes, 
which occurs after repeated cycles of cell death and 
compensatory proliferation in chronic hepatitis, appears to 
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Figure 6: Effect of TUDCA on the orthotopic and xenograft mouse models of HCC progression. A. Representative images 
of murine livers treated for 25 weeks with DEN injections followed by 5 weeks of TUDCA-supplemented or control drinking water. B. 
Reticulin staining of the DEN-treated livers for C. quantification of tumor burden.Scale bar: 100 μm. D. Real-time PCR analysis of the UPR 
targets Grp78 and Chop. E. Expression of Grp78, eIf2α, phospho-eIf2α, Chop, procaspase-12 and cleaved caspase-12 was detected using 
Western blotting. Results are representative of 2 independent experiments. F. Effect of indicated treatments on growth of HepG2 xenografts 
in athymic nude mice (n = 6). The volume of each tumor was measured for 33 days. Values represent the mean ± SD. G. At the end of the 
treatment period, animals were sacrificed and tumor weights were recorded. *p < 0.05, **p < 0.01.
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be an important factor in hepatocarcinogenesis [16, 40]. 
Apparently, increased hepatocyte apoptosis contributed 
to the development of HCC in our DEN-induced mouse 
model. TUDCA interrupts the positive feedback from UPR-
mediated apoptosis-induced hepatocarcinogenesis, leading to 
UPR activation by tumor microenvironmental stresses [11].
Finally, an oral treatment option for preventing HCC 
would be highly beneficial for cirrhotic patients with high 
HCC risk. In this study, we showed that TUDCA could 
represent a clinically applicable chemopreventive agent 
for HCC. Whether hepatocyte susceptibility to other 
carcinogens, such as viral replication or alcohol, can be 
limited by chemical chaperones will be of great interest.
In conclusion, our study demonstrates that 
supplementation with TUDCA diminishes carcinogen-
induced hepatotoxicity and prevents tumor induction by, 
at least partially, alleviating positive feedback from ER 
stress, inflammation and apoptosis in carcinogen-injured 
liver tissue.
MATERIALS AND METHODS
Animal studies
Ethics statement
The investigation was conducted in accordance with 
the ethical standards and according to the Declaration of 
Helsinki as well as the national and international guidelines. 
The investigation was also approved by the institutional 
review board of Ghent University (ECD 11/52).
Orthotopic model
Wild-type 129S2/SvPasCrl mice were purchased 
from Charles River (Belgium) and maintained as 
previously described [18]. In the preventive arm of the 
study, 5-week-old male mice were randomly divided into 
4 groups (n = 12 in each group). Three groups received 
weekly intraperitoneal DEN (35 mg/kg, in saline) 
injections for 25 weeks with either regular drinking water 
or drinking water supplemented with varying amounts 
of TUDCA (low dose of 60 mg/kg/day or high dose of 
300 mg/kg/day). Mice in the control group received 25 
weeks of saline injections and regular drinking water. In 
the therapeutic arm of the study, mice received DEN for 
25 weeks before being treated with saline- or TUDCA-
supplemented (low or high dose) drinking water for 
5 weeks (n = 12 in each group). In addition, 30 μg of 
tunicamycin was intraperitoneally injected in four naive 
30-week-old male 129S2/SvPasCrl mice 72 h before 
sacrifice. Blood was collected from the retro-orbital sinus 
under isoflurane anesthesia. After macroscopic evaluation 
and quantification of hepatic tumor number, all organs 
were fixed in 4% phosphate-buffered formaldehyde 
(Klinipath) and embedded in paraffin or snap frozen in 
liquid nitrogen. Hematoxylin/eosin and reticulin staining 
were performed to assess tumor burden, and the results 
were evaluated by two independent observers. Sirius Red 
staining enabled fibrosis assessment according to Metavir 
scoring.Serum alanine and aspartate aminotransferase 
(ALT and AST, respectively) levels were measured at the 
Lab of Clinical Biology, Ghent University Hospital.
Xenograft model
HepG2 cells (6×106) were re-suspended in 100 μl of 
serum-free media and mixed with 100 μl of Matrigel(BD 
Biosciences, Bedford, MA, USA). The cell preparation 
was injected subcutaneously into the right flank of 
8-week-old male athymic nude mice. Tumor volumes 
were calculated using the following formula: volume 
(mm3) = ab2/2; where b is the smaller dimension. When 
the mean tumor volume reached 150 mm3, animals were 
randomized into three groups (n = 6 in each group) as 
follows: regular drinking water, low-dose (60 mg/kg/day) 
TUDCA-supplemented drinking water and high-dose (300 
mg/kg/day) TUDCA-supplemented drinking water. Tumor 
dimensions were recorded two times per week with a 
digital caliper starting on the first day of treatment. Tumor 
weights were recorded at the time of sacrifice.
Cell culture
HepG2, BWTG3 and Hepa1-6 (ATCC, Virginia, 
USA) cells were cultured in DMEM supplemented 
Figure 7: Schematic overview outlining the mechanisms of the chemopreventive effects of TUDCA. 
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with 10% fetal bovine serum (Life Technologies, 
Ghent, Belgium). Cells were incubated for 48 h 
with tunicamycin (0.5 μg/ml), TUDCA (0.1–10 mM, 
Calbiochem, MA, USA), salubrinal (50 μM, Tocris, 
Bristol, UK), N-acetylcysteine (5 mM), H2O2 (1–5 
mM) or equal volumes of solvent. For direct cell 
counting, cells were trypsinised and counted in trypan 
blue. All reagents were obtained from Sigma (Diegem, 
Belgium) unless stated otherwise. Experiments were 
performed in quadruplicate and independently repeated 
three times.
Detailed information regarding choline positron 
emission tomography, caspase-3/7 activity, TUNEL 
apoptosis, RNA extraction, quantitative real-time PCR, 
western blot analysis, LDH, MTT, BrdU incorporation, 
lipid peroxidation, immunohistochemistry, multiplex 
microbead and spheroid invasion assays is provided in the 
Supporting Information.
Statistics
Statistical analyses were performed using SPSS 
version 21 (SPSS, Chicago, USA). Data are presented 
as the mean ± SD or fold change relative to expression 
in controls. Normally distributed data were subjected 
to unpaired student’s t-tests. Multiple groups were 
compared by one-way analysis of variance (ANOVA) 
with Bonferroni correction. Non-normally distributed 
data were tested using the Mann-Whitney U test. The 
chi-squared test was used to compare mortality. Student’s 
paired t-test was used to compare area or perimeter fold 
change. Reported p-values were two-sided and considered 
significant when less than 0.05.
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